The development of quality-assured generic medicines explained by Laurus Labs

Always wondered how a quality-assured generic medicine is being developed? Ms Sivalakshmi, Head of Analytical Development at Laurus Labs, gives us an insight of the development process within the company. The Medicines Patent Pool partners with Laurus Labs and 21 other generic manufacturers to increase access to affordable quality-assured generic medicines in low- and middle-income countries. The video was filmed in 2019 during a visit of the MPP team to India.

➡️ For more stories, visit our online channel: https://medicinespatentpool.org/stories/
Twitter:   / medspatentpool  
LinkedIn:   / medicines-patent-pool  

Contact: [email protected]

About the Medicines Patent Pool: The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC).